What was the overall market valuation of the US insulin biosimilars market in 2024?

The overall market valuation was $1.26 Million in 2024. Read More

What is the projected market valuation for the US insulin biosimilars market by 2035?

The projected valuation for 2035 is $2.74 Million. Read More

What is the expected CAGR for the US insulin biosimilars market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 7.31%. Read More

What were the valuations for rapid-acting biosimilars in 2024?

The valuation for rapid-acting biosimilars was $0.38 Million in 2024. Read More

What is the projected valuation for long-acting biosimilars by 2035?

The projected valuation for long-acting biosimilars by 2035 is $1.36 Million. Read More

How do the valuations for Type I and Type II diabetes biosimilars compare in 2024?

In 2024, both Type I and Type II diabetes biosimilars had valuations of $0.63 Million. Read More

What is the expected growth trend for premixed biosimilars from 2024 to 2035?

The expected growth trend for premixed biosimilars indicates a rise from $0.25 Million in 2024 to $0.55 Million by 2035. Read More

What segment of the US insulin biosimilars market shows the highest projected growth by 2035?

The segment of long-acting biosimilars shows the highest projected growth, reaching $1.36 Million by 2035. Read More

What does the market data suggest about the future of insulin biosimilars in the US?

The market data suggests a robust growth trajectory, with an increase in valuation from $1.26 Million in 2024 to $2.74 Million by 2035. Read More

US Insulin Biosimilars Market

Q: Which companies are considered key players in the US insulin biosimilars market?

Key players include Sanofi, Boehringer Ingelheim, Mylan, Sandoz, Teva, Fresenius Kabi, Celltrion, Amgen, and Roche. Read More

ID: MRFR/Pharma/18133-HCR

100 Pages

Vikita Thakur

Last Updated: April 06, 2026

US Insulin Biosimilars Market Research Report By Type (Rapid-acting biosimilars, Long-acting biosimilars, Premixed biosimilars) and By Indication (TYPE I DIABETES, TYPE II DIABETES) - Growth & Industry Forecast 2025 To 2035

US Insulin Biosimilars Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)7.31%

2024 Market Size$ 1.26 Million

2025 Market Size$ 1.35 Million

2035 Market Size$ 2.74 Million

Key Players

Sanofi

Boehringer Ingelheim

Mylan

Sandoz

Teva

Fresenius Kabi

Trends

Regulatory Support and Market Entry
Technological Advancements in Delivery Systems
Focus on Cost-Effectiveness

Opportunities

Rising Diabetes Prevalence
Cost Containment Initiatives
Regulatory Framework Enhancements

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Million)
  1. 4.1.1 Rapid-acting biosimilars
  2. 4.1.2 Long-acting biosimilars
  3. 4.1.3 Premixed biosimilars
2. 4.2 Healthcare, BY Indication (USD Million)
  1. 4.2.1 Type I Diabetes
  2. 4.2.2 Type II Diabetes
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Sanofi (FR)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Mylan (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sandoz (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Teva (IL)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Fresenius Kabi (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Celltrion (KR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Roche (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY INDICATION
4. 6.4 KEY BUYING CRITERIA OF HEALTHCARE
5. 6.5 RESEARCH PROCESS OF MRFR
6. 6.6 DRO ANALYSIS OF HEALTHCARE
7. 6.7 DRIVERS IMPACT ANALYSIS: HEALTHCARE
8. 6.8 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
9. 6.9 SUPPLY / VALUE CHAIN: HEALTHCARE
10. 6.10 HEALTHCARE, BY TYPE, 2024 (% SHARE)
11. 6.11 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
12. 6.12 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Million)
14. 6.14 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY INDICATION, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Insulin Biosimilars Market Segmentation

US Insulin Biosimilars Market By Type (USD Million, 2025-2035)

Rapid-acting biosimilars
Long-acting biosimilars
Premixed biosimilars

US Insulin Biosimilars Market By Indication (USD Million, 2025-2035)

Type I Diabetes
Type II Diabetes

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”